NCT05625685 is a NA clinical trial of Quitbuddy in Tobacco Use Disorder, sponsored by Bryan W. Heckman.

Who is sponsoring NCT05625685?

NCT05625685 is sponsored by Bryan W. Heckman.

What drugs are being tested in NCT05625685?

Interventions in NCT05625685: Quitbuddy, Control, SDoH Augmentation, SDoH Control.

What condition does NCT05625685 study?

NCT05625685 studies Tobacco Use Disorder, Tobacco Dependence.

Is NCT05625685 still recruiting?

NCT05625685 is currently withdrawn. Last updated 8 May 2024.

Last reviewed 2024-05-08 · How we verify

NCT05625685

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Equitable Smoking Relapse Prevention

Withdrawn NA Last updated 8 May 2024

What this trial tests

NA trial testing Quitbuddy in Tobacco Use Disorder. Withdrawn.

Timeline

2 October 2023

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	Bryan W. Heckman
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	other
Start date	2 October 2023
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	1 location across United States

Drugs / interventions tested

Quitbuddy
Control
SDoH Augmentation
SDoH Control

Conditions studied

Tobacco Use Disorder — all drugs for Tobacco Use Disorder →
Tobacco Dependence — all drugs for Tobacco Dependence →

Sponsor

Bryan W. Heckman

Who can join

21 and older, any sex, with Tobacco Use Disorder or Tobacco Dependence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test a GPS (Global Positioning System)-enabled smartphone app (QuitBuddy) in current smokers. The main questions it aims to answer are: * Is Quitbuddy a good treatment for quitting smoking and "staying quit"? * Will a second treatment that connects people to help for their social and financial needs improve Quitbuddy? Participants will: * get nicotine lozenges in the mail * check in with the study team to report on their quitting progress after 1 day, 1 week, 1 month, 2 months, 3 months, and 6 months Researchers will compare Quitbuddy to an app made by the National Cancer Institute to see if Quitbuddy is better for helping people stay quit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tobacco Use Disorder

Currently open trials in the same condition.

NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT06678672 — Contingency Management for Veteran Smokers Undergoing Major Elective Surgery · NA · recruiting
NCT06006143 — Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2 · Phase 2 · active not recruiting
NCT06883162 — Cannabis-Tobacco Co-Use Treatment Study · Phase 3 · recruiting
NCT06798324 — tDCS Plus Varenicline for Smoking Cessation · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05625685 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bryan W. Heckman
Last refreshed: 8 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05625685.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing